CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...
Company
Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration...
Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC
Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...
Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate
Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga...
InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales
China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...
Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform
Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion...
Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China
China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...
Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial
Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...
Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022,...
JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products
JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series...
IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China
China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational...
Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues...
Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has...
Daiichi Sankyo’s Enhertu Accepted for Review in China for HER2-Low Breast Cancer
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd,...
Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...
WuXi STA Breaks Ground on New US Manufacturing Site in Delaware
WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...
ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...
Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...
LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...